Koster, D.( D. Koster)
patient ﬁbatide resource treatment resource consumption trial european ﬀectivenes hospital epti ﬁbatide infarction cost-e ﬀectiveness ratios country consumption pursuit month cost e ﬀectiveness 6 months placebo european patients cost-e syndrome 30 days di ﬀerence pursuit trial intervention cost cost /yols epti ﬁbatide patients survival ratio analysis ﬀerence death procedure outcome group platelet end-point heart table analyses eur heart j resource use event arteriography /iiia epti ﬁbatide use health angina life expectancy investigator population percutaneou management receptor study di ﬀerences glycoprotein 0·001 disease discount mi =myocardial infarction europe arteriography rate countries technology creatine kinase treatment costs treatment groups patient outcomes european countries issue january elevation e ﬀects ﬀerent germany length measure expectancy artery
1 Most Recent Publications
Cost effectiveness of eptifibatide in acute coronary syndromes; an economic analysis of Western European patients enrolled in the PURSUIT trial. The Platelet IIa/IIb in unstable Angina: Receptor Suppression Using Integrilin Therapy.
Brown, R.E. Henderson, R.A. Koster, D. Hutton, J. Simoons, M.L.